BACKGROUND: Oral anticancer medications (OAM) make administration more convenient for patients, but shifts the responsibility of care from clinical providers to the patients themselves. Following an institutional pilot study showing inadequate understanding and adherence among vulnerable patients taking OAM, a longitudinal intervention was developed using an oncology specialty pharmacist and medication navigators to enhance OAM understanding and adherence. METHODS: Patients initiating OAM were approached for four formalized teaching and check-in sessions, supplemented with medication information sheets and individualized calendars. At each session, participants were assessed on their OAM understanding and adherence using teach-back and validated measures. A study evaluation elicited feedback from participants on the usefulness of the intervention. RESULTS: Of 80 eligible patients, 58 (72.5%) received formal OAM teaching from the specialty pharmacist. Of those, 54 (93.1%) enrolled in the study with 39 (72%) completing the intervention for final analysis. At study completion, all participants adequately understood OAM taking, but 41.0% had inadequate understanding of OAM handling. Throughout the study, participants reported issues that were addressed by the intervention team (28.2% to 31.6%) as well as those requiring additional assistance from the treatment team (26.3% to 38.5%), Most participants found the intervention to be very beneficial (initial evaluation, 86.5%; final evaluation, 76.9%). CONCLUSIONS: This pilot intervention addressed gaps identified by our institutional assessment through formalized OAM teaching and follow-up. Improved understanding of taking and handling OAM through this subsequent study illustrated the enhanced effect of a multidisciplinary and multicomponent intervention to better educate and support patients on OAM.
BACKGROUND: Oral anticancer medications (OAM) make administration more convenient for patients, but shifts the responsibility of care from clinical providers to the patients themselves. Following an institutional pilot study showing inadequate understanding and adherence among vulnerable patients taking OAM, a longitudinal intervention was developed using an oncology specialty pharmacist and medication navigators to enhance OAM understanding and adherence. METHODS:Patients initiating OAM were approached for four formalized teaching and check-in sessions, supplemented with medication information sheets and individualized calendars. At each session, participants were assessed on their OAM understanding and adherence using teach-back and validated measures. A study evaluation elicited feedback from participants on the usefulness of the intervention. RESULTS: Of 80 eligible patients, 58 (72.5%) received formal OAM teaching from the specialty pharmacist. Of those, 54 (93.1%) enrolled in the study with 39 (72%) completing the intervention for final analysis. At study completion, all participants adequately understood OAM taking, but 41.0% had inadequate understanding of OAM handling. Throughout the study, participants reported issues that were addressed by the intervention team (28.2% to 31.6%) as well as those requiring additional assistance from the treatment team (26.3% to 38.5%), Most participants found the intervention to be very beneficial (initial evaluation, 86.5%; final evaluation, 76.9%). CONCLUSIONS: This pilot intervention addressed gaps identified by our institutional assessment through formalized OAM teaching and follow-up. Improved understanding of taking and handling OAM through this subsequent study illustrated the enhanced effect of a multidisciplinary and multicomponent intervention to better educate and support patients on OAM.
Authors: Vittorio Gebbia; Giuseppe Bellavia; Francesco Ferraù; Maria Rosaria Valerio Journal: Expert Opin Drug Saf Date: 2011-12-13 Impact factor: 4.250
Authors: N Lynn Henry; Faouzi Azzouz; Zereunesay Desta; Lang Li; Anne T Nguyen; Suzanne Lemler; Jill Hayden; Karineh Tarpinian; Elizabeth Yakim; David A Flockhart; Vered Stearns; Daniel F Hayes; Anna Maria Storniolo Journal: J Clin Oncol Date: 2012-02-13 Impact factor: 44.544
Authors: Roderick J Little; Ralph D'Agostino; Michael L Cohen; Kay Dickersin; Scott S Emerson; John T Farrar; Constantine Frangakis; Joseph W Hogan; Geert Molenberghs; Susan A Murphy; James D Neaton; Andrea Rotnitzky; Daniel Scharfstein; Weichung J Shih; Jay P Siegel; Hal Stern Journal: N Engl J Med Date: 2012-10-04 Impact factor: 91.245
Authors: Michael N Neuss; Martha Polovich; Kristen McNiff; Peg Esper; Terry R Gilmore; Kristine B LeFebvre; Lisa Schulmeister; Joseph O Jacobson Journal: J Oncol Pract Date: 2013-03 Impact factor: 3.840
Authors: Gennaro A Paolella; Andrew D Boyd; Scott M Wirth; Sandra Cuellar; Neeta K Venepalli; Stephanie Y Crawford Journal: Pharmacy (Basel) Date: 2018-03-08
Authors: Sarah M Belcher; Emily Mackler; Benyam Muluneh; Pamela K Ginex; Mary K Anderson; Elizabeth Bettencourt; Ryan K DasGupta; Jennifer Elliott; Erica Hall; Michelle Karlin; Diana Kostoff; Victoria K Marshall; Vanessa E Millisor; Maegan Molnar; Susan M Schneider; Janelle Tipton; Susan Yackzan; Kristine B LeFebvre; Kapeena Sivakumaran; Haya Waseem; Rebecca L Morgan Journal: Oncol Nurs Forum Date: 2022-06-17 Impact factor: 1.803